Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities

Circulation

Volumn 101, Issue 17, 2000, Pages 2071-2077

  Jollis, James G ^a   Landolfo, Carolyn K ^a   Kisslo, Joseph ^a   Constantine, Ginger D ^b   Davis, Kelly D ^b   Ryan, Thomas ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

Echocardiography; Epidemiology; Regurgitation; Valves

Indexed keywords

FENFLURAMINE; PHENTERMINE;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART MURMUR; HEART VALVE REGURGITATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; OBESITY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL;

EID: 0034595380     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.17.2071     Document Type: Article

References (12)

1. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51:642-646.
2. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
3. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep. 1997;46:1061-1066.
4. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339:719-724.
5. Khan MA, Herzog CA, St. Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339: 713-718.
6. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 1998;339: 725-732.
7. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
8. Carabello BA, Crawford FA. Valvular heart disease. N Engl J Med. 1997;337:32-41.
9. Bonow RO, Carabello B, de Leon AC, Edmunds LH, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 1998;98:1949-1984.
10. Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord. 1990;19:43-51.
11. Wood AJJ, Stein CM, Woosley RD. Making medicines safer: the need for an independent drug safety board. N Engl J Med. 1998;339:1851-1854.
12. Kimmel SE, Keane MG, Crary JL, Jones J, Kinman JL, Beare J, Sammel M, Sutton MS, Strom BL. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol. 1999;84:304-308.